

RECEIVED
APR 10 2001
SHEET 1 of 7
TECH CENTER 1801/800

Form PTO-1449	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DKT. NO. BAYER 1 D1	SERIAL NO. 09/755,060
		APPLICANT Jill E. WOOD <i>et al.</i>	
		FILING DATE January 8, 2001	GROUP 1626

INFORMATION DISCLOSURE STATEMENT
BY APPLICANT

(Use several sheets if necessary)

U.S. PATENT DOCUMENTS

Examiner Initial		Document Number	Date	Name	Class	Subclass	Filing Date
75H	AA	3,823,161	07/09/74	Lesser	514	447X	
	AB	5,130,331	07/14/92	Pascual	514	447	
	AC	4,808,588	02/28/89	King	514	212	
	AD	3,424,760	01/28/69	Helsley et al.	548	557	
	AE	3,424,761	01/28/69	Helsley et al.	548	557	
	AF	3,424,762	01/28/69	Helsley et al.	548	637	
	AG	4,071,524	01/31/78	Banitt	548	557	
	AH	4,111,683	09/05/78	Singer	549	480X	
	AI	4,437,878	03/20/78	Acker et al.	549	069	
	AJ	4,643,849	02/17/87	Hirai et al.	540	953	
75H	AK	5,773,459	06/30/98	Tang et al.	514	445	
75H	AL	5,508,288	04/16/96	Forbes et al.			
75H	AM	4,062,861	12/13/77	Yukinaga et al.			
	AN	4,111,680	09/05/78	Yukinaga et al.			
	AO	4,116,671	09/26/78	Yukinaga et al.			
	AP	4,212,981	07/15/80	Yukinaga et al.			
	AQ	5,162,360	11/10/92	Creswell et al.			
	AR	4,514,571	04/30/85	Nakai et al.			
	AS	3,754,887	08/28/73	Brantley			
	AT	3,646,059	02/29/72	Brantley			
	AU	5,696,138	12/9/97	Olesen et al.			
	AV	5,780,483	7/14/98	Widdowson et al.			
	AW	4,405,644	9/20/83	Kabbe et al.			
	AX	4,473,579	9/25/84	Devries et al.			
	AY	4,526,997	7/2/85	O'Doherty et al.			
	AZ	4,468,380	8/28/84	O'Doherty et al.			
	BA	4,623,662	11/18/86	De Vries			
	BB	4,985,449	1/15/91	Haga et al.			
	BC	5,312,820	5/17/94	Ashton et al.			
	BD	4,410,697	10/18/83	Török et al.			
	BE	4,001,256	1/4/97	Callahan et al.			
75H	BF	5,399,566	3/21/95	Katano et al.			
75H	BG	5,500,424	3/19/96	Nagamine et al.			



Sheet 2 of 7

104	BM	5,597,233	1/28/97	Freed et al.	435	194	APR 10 2001
	BI	4,183,854	1/80	Crossley			
	BJ	3,828,001	8/74	Broad et al.	549	069	
	BK	4,740,520	4/88	Hallenbach et al.	514	447	
	BL	5,319,099	6/7/94	Kamata et al.			

FOREIGN PATENT DOCUMENTS

Examiner Initial	Document Number	Date	Country	Class	Subclass	Translation	
						Yes	No
104	BM	EP 335156	03/11/89	European	T		X
	BN	EP 459887	05/28/91	European	T		X
	BO	EP 371876	11/28/89	European	T		X
	BP	93/24458	12/9/93	WO		X	
	BQ	2,146,707	10/12/95	Canada		X	
	BR	96/40673	12/19/96	WO		X	
	BS	94/14801	07/07/94	WO		X	
	BT	94/25012	11/10/94	WO		X	
	BU	1,590,870	06/10/81	England		X	
	BV	93/18028	09/16/93	WO		X	
	BW	94/18170	08/18/94	WO		X	
	BX	DE 3305866 A1	02/19/83	Germany			X
	BY	95/02591	01/26/95	WO		X	
	BZ	95/13067	05/18/95	WO		X	
	CA	95/07922	03/23/95	WO		X	
	CB	95/31451	11/23/95	WO		X	
	CC	A1 96/40675	12/19/96	WO		X	
	CD	JP 53 086033	7/29/78	Japan			
	CE	JP 51 063170	1/6/76	Japan			
	CF	97/49400	12/31/97	WO			
	CG	97/49399	12/31/97	WO			
	CH	96/40673	12/19/96	WO			
	CI	99/00357	1/7/99	WO			
	CJ	97/45400	12/4/97	WO			
	CK	96/02112	3/8/90	WO			
	CL	99/00370	1/7/99	WO			
	CM	97/29743	8/21/97	WO			
	CN	98/22432	5/28/98	WO			
	CO	96/25157 A1	8/22/96	WO			
104	CP	97/40028 A1	10/30/97	WO			



RECEIVED
APR 10 2001
TECH CENTER 160012300

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)	
167H CQ	Dumas, J., "CAS Substructure," May 6, 1997, pages 1-29.
CR	Scott, Bill, "Substructure (Patent Families)," August 11, 1997, pages 1-19.
CS	Scott, Bill, "Substructure #2," November 25, 1997, pages 1-3.
CT	"Beilstein number" Collection, 28 pages.
CU	"Beilstein Collection," 4 pages.
CV	Scott, Bill, "Substructure Search," December 2, 1997, pages 1-51.
CX	Substructure Search, pages 1-30.
CY	Derwent World Patents Index Search, pages 20-26.
CZ	Abstract of EP 116,932 (Date: 08/29/1984)
DA	Abstract of EP 676,395 (Date: 10/11/1995)(U.S. equivalent 5,698,581)
DB	Abstract of EP 202,538 (Date: 11/26/1986)
DC	Abstract of EP 16,371 (Date: 10/01/1980)
DD	Avruch et al., "Raf meets Ras: completing the framework of a signal transduction pathway", TIBS 19; July 1994; pp. 279-2823.
DE	White, A. D., et al., "Heterocyclic Ureas: Inhibitors of Acyl-CoA:Cholesterol O-Acyltransferase as Hypocholesterolemic Agents," June 6, 1996, pages 4382-95.
DF	Audia, James E., et al., "Potent, Selective Tetraphydro- β -carboline Antagonists of the Serotonin 2B (5HT _{2B}) Contractile Receptor in the Rat Stomach Fundus," January 22, 1996, pages 2773-80.
DG	Forbes, Ian T., "N-(1-Methyl-5-indolyl)-N'-(3-methyl-5-isothiazolyl)urea: A Novel, High-Affinity 5-HT _{2B} Receptor Antagonist," March 17, 1995, pages 855-57.
DH	Boulton, A. J., et al., "Heterocyclic Rearrangements. Part X. ¹ A Generalised Monocyclic Rearrangement," 1967, 2005-07.
DI	N. S. Magnuson, et al., "The Raf-1 serine/threonine protein kinase," Cancer Biology, vol. 5, 1994, pages 247-253.
DJ	G. Daum, et al., The ins and outs of Raf Kinases,," TIBS 19, November 1994, pages 474-80.
DK	W. Kolch, et al., "Raf-1 protein kinase is required for growth of induced NIH/3T3 cells," Letters to Nature, vol. 349, January 31, 1991, page 226-28.
DL	M. Fridman, et al., "The Minimal Fragments of c-Raf-1 and NF1 That Can Suppress v-Ha-Ras-Induced Malignant Phenotype," The Journal of Biological Chemistry, vol. 269, no. 48, December 2, 1994, pages 30105-108.
DM	G. L. Bolton, et al., Chapter 17. Ras Oncogene Directed Approaches in Cancer Chemotherapy, Annual Reports In Medicinal Chemistry, vol. 29, 1994, pages 165-74.
DN	J. L. Bos, "ras Oncogenes in Human Cancer: A Review," Cancer Research, vol. 49, September 1, 1989, pages 4682-89.
DO	Michaelis, Justus, Liebigs Ann. Chem. (JLACBF) 397, 1913, 143.
DP	B. P. Monia, et al., "Antitumor activity of a phosphorothioate antisense oligodeoxynucleotide targeted against C-raf kinase," Nature Medicine, vol. 2, No. 6, June 1996, pages 668-75.
DQ	Lee, et al., Bicyclic Imidazoles as a Novel Class of Cytokine Biosynthesis Inhiibitors," N.Y. Academy of Science, 1993, pages 149-70.
DR	F. Lepage, et al., "New N-aryl isoxazolecarboxamides and N-isoxazolybenzamides as anticonvulsant agents," Eur. J. Med. Chem, vol. 27, 1992, pages 581-93.
DS	Ridley, et al., "Actions of IL-1 are Selectively Controlled by p38 Mitogen-Activated Protein Kinase," The American Association of Immunologists, 1997, page 3165-73.
167H DT	Chemical Abstract, Vol. 116, No. 21, 25 May 1992, pages 741-742.




U.S. PATENT DOCUMENTS

Sheet 4 of 7
APR 1 2001
RECEIVED
TECHNICAL CENTER 1600 2900

Examiner Initial	Document Number	Date	Name	Class	Subclass	Filing Date
<i>[Signature]</i>	DU 5,059,614	10/22/91	Lepage et al.	I	I	
	DV 3,743,498	7/3/73	Brantley	I	I	
	DW 3,547,940	12/15/70	Brantley	I	I	
	DX 5,432,468	7/11/95	Moriyama et al.	I	I	
	DY 1,742,156	2/31	Fitzky	I	I	
	DZ 2,046,375	7/36	Goldstein et al.	I	I	
	EA 2,093,265	9/36	Coffby et al.	I	I	
	EB 2,288,422	6/42	Rohm	I	I	
	EC 2,683,082	7/54	Hill et al.	I	I	
	ED 2,745,874	5/56	Schetty et al.	I	I	
	EF 2,781,330	2/57	Downey	I	I	
	EG 2,867,659	1/59	Model et al.	I	I	
	EH 2,877,268	3/59	Applegate et al.	I	I	
	EI 2,960,488	11/60	Tamblyn et al.	I	I	
	EJ 3,689,550	9/72	Schellenbaum et al.	I	I	
	EK 3,860,645	1/95	Nikawitz	I	I	
	EL 5,423,905	6/95	Fringeli	I	I	
	EM 2,973,386	2/61	Weldon	I	I	
	EN 3,230,141	1/66	Frick et al.	I	I	
	EO 4,863,924	9/89	Haga et al.	I	I	
	EP 4,511,571	4/85	Böger et al.	I	I	
	EQ 4,173,638	11/79	Nishiyama et al.	I	I	
	ER 4,173,637	11/79	Nishiyama et al.	I	I	
	ES 4,820,871	4/89	Kissener et al.	I	I	
	ET 4,983,605	1/91	Kondo et al.	I	I	
	EU 5,098,907	3/92	Kondo et al.	I	I	
	EV 5,036,072	7/91	Nakajama et al.	I	I	
	EW 5,470,882	11/95	Dixon et al.	I	I	
	EX 5,429,918	7/95	Seto et al.	I	I	
	EY 3,151,023	9/64	Martin	I	I	
	EZ 3,200,035	8/65	Martin et al.	I	I	
<i>[Signature]</i>	FA 5,807,891	9/15/98	Bold et al.	I	I	
<i>[Signature]</i>	FB 4,009,847	3/1/77	Aldrich et al.	I	I	

FOREIGN PATENT DOCUMENTS

Examiner Initial	Document Number	Date	Country	Class	Subclass	Translation	
						Yes	No
<i>[Signature]</i>	FC 95/33458	12/14/95	WO	I	I		
	FD 0 771 333	3/57	Great Britain	I	I		
	FE 0 921 682	3/63	Great Britain	I	I		
	FF 0 253 997	2/88	East Germany	I	I		
<i>[Signature]</i>	FG 0 405 233	1/91	Europe	I	I		



Sheet 5 of 7
RECEIVED
11-10-2001
CENTRAL
11-10-2001

101	FH	1 457 67	9/66	France			
	FI	0 487 014	12/29	Germany			
	FJ	0 511 468	10/30	Germany			
	FK	0 523 437	5/31	Germany			
	FL	44 2569	2/69	Japan			
	FM	55 98152	7/80	Japan			
	FN	94 22807	10/94	WIPO			
	FO	3 532 47	3/91	Japan			
	FP	0 828 231	10/56	Great Britain			
	FQ	50-149668	11/75	Japan			
	FR	55-162772	12/80	Japan			
	FS	50-76072	6/75	Japan			
	FT	51-80862	7/76	Japan			
	FU	50-77375	6/75	Japan			
	FV	55-124763	9/80	Japan			
101	FW	0 502 504 A1	9/92	Europe			

OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, etc.)

101	FX	Tarzia, G. et al. "Whythesis and anti-inflammatory properties of some pyrrolo(1H,3H)[3,4]pyrimidin-2-ones and pyrrolo(1H,3H)[3,4-d]pyrimidin-2-ones and pyrrolo(1H,3H)-pyrimidin-2-ones. Chemical Abstracts. 27 August 1979, No. 74558p; page 594.
	FY	
	FZ	

Examiner

Woyd A. Legal

Date Considered

11-14-2001

Form PTO 1449 (Modified)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY DOCKET NO. BAYER 1 D1		SERIAL NO. 69/755,060	
LIST OF REFERENCES CITED BY APPLICANT <div style="border: 1px solid black; border-radius: 50%; padding: 10px; width: 150px; margin: 10px auto; text-align: center;"> OIPF APR 9 2001 PATENT & TRADEMARK OFFICE </div>				APPLICANT Jill E. WOOD et al.		FILING DATE JANUARY 8, 2001	
				GROUP 1628			

U.S. PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB CLASS	FILING DATE IF APPROPRIATE
<i>TSB</i>	AA	5,698,581	12/16/97	Kleemann et al.	I	I	
<i>TSB</i>	AB	4,760,063	07/26/88	Hallenbach et al.	I	I	
<i>TSB</i>	AC	4,240,820	12/23/80	Dickore et al.	I	I	
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						
	AL						
	AM						
	AN						

FOREIGN PATENT DOCUMENTS						
		DOCUMENT NUMBER	DATE	COUNTRY	TRANSLATION YES/NO Sub. NO	
<i>TSB</i>	AO	DE 35 29 747 A1	8/20/85	Germany	I	X
<i>TSB</i>	AP	DE 35 40 377 A1	11/14/85	Germany	I	X
<i>TSB</i>	AQ	WO 00/17175	09/16/99	WO		
	AR					
	AS					
	AT					
	AU					
	AV					

OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, etc.)		
<i>TSB</i>	AW	Abstract of EP 676,395 (U.S. equivalent 5,698,581)
<i>TSB</i>	AX	Abstract of EP 4931 (U.S. equivalent 4,240,820)
<i>TSB</i>	AY	Abstract of EP 116,932
<i>TSB</i>	AZ	Abstract of EP 202,538

Examiner <i>Klaus D. Hugel</i>	Date Considered <i>11/14/2001</i>
--------------------------------	-----------------------------------

*Examiner: Initial if reference is considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form PTO 1449 (Modified)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY DOCKET NO. BAYER-1 D1		SERIAL NO. 09/755,060	
LIST OF REFERENCES CITED BY APPLICANT <div style="position: absolute; top: 50px; left: 100px; border: 1px solid black; border-radius: 50%; padding: 10px; transform: rotate(-15deg);"> RECEIVED APR 10 2001 PATENT & TRADEMARK OFFICE </div>				APPLICANT Jill E. WOOD et al.		GROUP 1626	
				FILING DATE January 8, 2001			
U.S. PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB CLASS	FILING DATE IF APPROPRIATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						
	AL						
	AM						
	AN						
FOREIGN PATENT DOCUMENTS							
		DOCUMENT NUMBER	DATE	COUNTRY	TRANSLATION YES NO		
	AO						
	AP						
	AQ						
	AR						
	AS						
	AT						
	AU						
	AV						
OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, etc.)							
<i>7016</i>	AW	T. Murata et al., "Facile synthesis of new pyrrolo[3,4-d]pyrimidine-2,4-diones", Chemical and Pharmaceutical Bulletin, Vol. 22, 1974, pp. 1212-13 (XP-000973679)					
↑ ↓	AX	M.T. Garcia-Lopez et al., "New routes for the synthesis of pyrrolo[3,2-d]- and -[2,3-d]-pyrimidine systems starting from a common pyrrole derivative", Journal of the Chemical Society, Perkin Trans. 1, Vol. 1978, 1978, pp. 483-7 (XP-000973638)					
<i>7211</i>	AY	Abstract of EP 16,371 (Date: 10/01/1980)					
	AZ						
Examiner <i>Wayne D. Hugel</i>					Date Considered <i>11-14-2001</i>		

*Examiner: Initial if reference is considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.